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Abstract
© 2016, © International Headache Society 2016. Background: Blocking the pro-nociceptive
action of CGRP is one of the most promising approaches for migraine prophylaxis. The aim of
this study was to explore a role for CGRP as a neuroprotective agent for central and peripheral
neurons. Methods: The viability of isolated rat trigeminal, cortical and cerebellar neurons was
tested by fluorescence vital assay. Engagement of Nrf2 target genes was analyzed by qPCR. The
neuroprotective  efficacy  of  CGRP in  vivo  was  tested  in  mice  using  a  permanent  cerebral
ischemia model. Results: CGRP prevented apoptosis induced by the amino acid homocysteine in
all three distinct neuronal populations. Using a set of specific kinase inhibitors, we show the role
of multi-kinase signaling pathways involving PKA and CaMKII in neuronal survival.  Forskolin
triggered a very similar signaling cascade, suggesting that cAMP is the main upstream trigger
for  multi-kinase  neuroprotection.  The  specific  CGRP  antagonist  BIBN4096  reduced  cellular
viability, lending further support to the proposed neuroprotective function of CGRP. Importantly,
CGRP was neuroprotective against permanent ischemia in mice. Conclusion: Our data show an
unexpected  ‘positive’  role  for  the  endogenous  pro-nociceptive  migraine  mediator  CGRP,
suggesting  more  careful  examination  of  migraine  prophylaxis  strategy  based  on  CGRP
antagonism although  it  should  be  noted  that  homocysteine  induced  apoptosis  in  primary
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